AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22964932 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory physiotherapy (MH combined with ERCC)
Number of subjects: 49
Study 22964932 — intervention group
Group type: COMPARATOR
Intervention: Standard nursing care (Control)
Number of subjects: 49
Study 20920766 — intervention group
Group type: EXPERIMENTAL
Intervention: OM-85 BV
Number of subjects: 75
Study 17595451 — intervention group
Group type: EXPERIMENTAL
Intervention: Euthyrox (50 mkg daily) after PEI
Number of subjects: 55
Study 17595451 — intervention group
Group type: COMPARATOR
Intervention: PEI alone (control group)
Number of subjects: 55
Study 15514883 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: pulp removed before replantation, calcium hydroxide filled in root canals, routine condensation after half a year
Number of subjects: 49
Study 15514883 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: pulp removed one week after replantation
Number of subjects: 49
Study 15514883 — intervention group
Group type: COMPARATOR
Intervention: Group C: pulp removed until pulp disease
Number of subjects: 49
Study 11230418 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-LPS IgM ELISA
Number of subjects: 0
Study 11230418 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-LPS IgG ELISA
Number of subjects: 0
Study 11230418 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-LPS IgA ELISA
Number of subjects: 0
Study 11230418 — intervention group
Group type: EXPERIMENTAL
Intervention: antiflagellum IgG ELISA
Number of subjects: 0
Study 11230418 — intervention group
Group type: EXPERIMENTAL
Intervention: Widal TO test
Number of subjects: 0
Study 11230418 — intervention group
Group type: EXPERIMENTAL
Intervention: Widal TH test
Number of subjects: 0
Study 11230418 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-serotype Typhi IgM dipstick assay
Number of subjects: 0
Study 11230418 — intervention group
Group type: EXPERIMENTAL
Intervention: IDeaL TUBEX
Number of subjects: 0
Study 11230418 — intervention group
Group type: COMPARATOR
Intervention: Widal TO test vs anti-LPS IgM ELISA
Number of subjects: 0
Study 9764720 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilvadipine
Number of subjects: 12
Study 9764720 — intervention group
Group type: COMPARATOR
Intervention: Terazosin
Number of subjects: 12
Study 8171944 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 30
Study 8171944 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 30
Study 3064774 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (C)
Number of subjects: 2342
Study 3064774 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide + methotrexate + 5-fluorouracil (CMF)
Number of subjects: 2342
Study 3064774 — intervention group
Group type: EXPERIMENTAL
Intervention: No systemic treatment (0)
Number of subjects: 2342
Study 3064774 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF for 9 months
Number of subjects: 2342
Study 3064774 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT)
Number of subjects: 2342
Study 3064774 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) for 1 year
Number of subjects: 2342
Study 3064774 — intervention group
Group type: COMPARATOR
Intervention: No further treatment
Number of subjects: 2342
Study 29513119 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision-making (SDM) responses by healthcare professionals (HCPs) as described in a case-study reflection assignment
Number of subjects: 42
Study 27905916 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 to 250 mg lisdexamfetamine, dispensed daily on site, over an 8-week period
Number of subjects: 20
Study 27905916 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling as standard care
Number of subjects: 20
Study 25124303 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine self-administration
Number of subjects: 32
Study 22080588 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline 1 mg b.i.d. for 12 weeks
Number of subjects: 659
Study 22080588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 659
Study 22080588 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline 1 mg b.i.d.
Number of subjects: 659
Study 20707210 — intervention group
Group type: EXPERIMENTAL
Intervention: Songling Xuemaikang + Shuxuetong + Aspirin enterie coated tablets
Number of subjects: 160
Study 20707210 — intervention group
Group type: COMPARATOR
Intervention: Shuxuetong + Aspirin enterie coated tablets
Number of subjects: 160
Study 18071731 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 50
Study 18071731 — intervention group
Group type: COMPARATOR
Intervention: Full macular translocation (FMT)
Number of subjects: 50
Study 16437364 — intervention group
Group type: EXPERIMENTAL
Intervention: D(3) radical resection
Number of subjects: 272
Study 16437364 — intervention group
Group type: COMPARATOR
Intervention: D(2) radical resection
Number of subjects: 272
Study 14729236 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 20
Study 14729236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11306220 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocational education services
Number of subjects: 371
Study 11306220 — intervention group
Group type: EXPERIMENTAL
Intervention: Group services
Number of subjects: 371
Study 11306220 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater number of all inpatient services
Number of subjects: 371
Study 9550511 — intervention group
Group type: EXPERIMENTAL
Intervention: Subacute rehabilitation in a hospital rehabilitation unit
Number of subjects: 251
Study 9550511 — intervention group
Group type: COMPARATOR
Intervention: Health services in the municipality (Control)
Number of subjects: 251
Study 11835076 — intervention group
Group type: EXPERIMENTAL
Intervention: HCTZ plus perindopril 2 mg
Number of subjects: 208
Study 11835076 — intervention group
Group type: EXPERIMENTAL
Intervention: HCTZ plus perindopril 4 mg
Number of subjects: 208
Study 11835076 — intervention group
Group type: EXPERIMENTAL
Intervention: HCTZ plus perindopril 8 mg
Number of subjects: 208
Study 11835076 — intervention group
Group type: COMPARATOR
Intervention: HCTZ plus placebo
Number of subjects: 208
Study 11835076 — intervention group
Group type: EXPERIMENTAL
Intervention: HCTZ plus perindopril (combined)
Number of subjects: 208
Study 3284266 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroral opioid therapy (SO)
Number of subjects: 0
Study 3284266 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural opioid by a conventional tunnelled epidural catheter (CE)
Number of subjects: 0
Study 3284266 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural catheter connected to an implanted injection port (Port)
Number of subjects: 0
Study 3284266 — intervention group
Group type: COMPARATOR
Intervention: Epidural techniques (CE and Port)
Number of subjects: 0
Study 30738711 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicryl Plus sutures (group 1)
Number of subjects: 320
Study 30738711 — intervention group
Group type: COMPARATOR
Intervention: Vicryl sutures (group 2)
Number of subjects: 320
Study 30738711 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Vicryl Plus and Vicryl)
Number of subjects: 320
Study 30738711 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicryl Plus sutures
Number of subjects: 320
Study 30079329 — intervention group
Group type: COMPARATOR
Intervention: Lactulose
Number of subjects: 87
Study 30079329 — intervention group
Group type: COMPARATOR
Intervention: L‐ornithine L‐aspartate
Number of subjects: 87
Study 30079329 — intervention group
Group type: COMPARATOR
Intervention: Rifaximin
Number of subjects: 87
Study 30079329 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 87
Study 27386641 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine Tablet (600 mg, once per day) combined with Jianpi Bushen Recipe (twice per day)
Number of subjects: 90
Study 27386641 — intervention group
Group type: COMPARATOR
Intervention: Telbivudine Tablet alone
Number of subjects: 90
Study 24607797 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 μg misoprostol vaginally 6 hours before HSG
Number of subjects: 168
Study 24607797 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg diclofenac potassium orally 45 to 60 minutes before HSG
Number of subjects: 168
Study 24607797 — intervention group
Group type: COMPARATOR
Intervention: No medication (control group)
Number of subjects: 168
Study 23189083 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (90 min/day, 2 days/week, 80 times for 12 months)
Number of subjects: 100
Study 23189083 — intervention group
Group type: COMPARATOR
Intervention: Education control group
Number of subjects: 100
Study 20394870 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 ethyl esters (1 g/day)
Number of subjects: 63
Study 20394870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 17385961 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-enhanced motivational intervention (PMI)
Number of subjects: 36
Study 17385961 — intervention group
Group type: COMPARATOR
Intervention: Individual motivational intervention (IMI)
Number of subjects: 36
Study 15565439 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium citrate (60 mEq/day) for 1 month
Number of subjects: 30
Study 11865829 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PXF)
Number of subjects: 194
Study 11865829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study 10539755 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sn-2 formula
Number of subjects: 203
Study 10539755 — intervention group
Group type: COMPARATOR
Intervention: Standard formula (control)
Number of subjects: 203
Study 10539755 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-fed infants
Number of subjects: 203
Study 7774036 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Number of subjects: 63
Study 1692612 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine surfactant therapy
Number of subjects: 32
Study 1692612 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 389827 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacampicillin (800 mg t.i.d. for 10 days)
Number of subjects: 72
Study 389827 — intervention group
Group type: COMPARATOR
Intervention: Pivampicillin (700 mg t.i.d. for 10 days)
Number of subjects: 72
Study 31997387 — intervention group
Group type: EXPERIMENTAL
Intervention: WOWW intervention
Number of subjects: 413
Study 31997387 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 413
Study 28945060 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized purified flavonoid fraction (MPFF) 1000 mg daily for 2 weeks before and for at least 2 months after sclerotherapy
Number of subjects: 60
Study 28945060 — intervention group
Group type: COMPARATOR
Intervention: Sclerotherapy alone (control)
Number of subjects: 60
Study 27612500 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid closed-loop insulin delivery
Number of subjects: 12
Study 25739243 — intervention group
Group type: EXPERIMENTAL
Intervention: Skeletal traction
Number of subjects: 68
Study 25739243 — intervention group
Group type: COMPARATOR
Intervention: Skin traction
Number of subjects: 68
Study 25739243 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 68
Study 24305085 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with immediate feedback for each session
Number of subjects: 180
Study 24305085 — intervention group
Group type: COMPARATOR
Intervention: Treatment without feedback
Number of subjects: 180
Study 20429841 — intervention group
Group type: EXPERIMENTAL
Intervention: 4‐Oxo‐4,5,6,7‐tetrahydro‐1H‐indole‐3‐carboxylic acid (1)
Number of subjects: 0
Study 18199015 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided imagery therapy (listening to a 25-minute guided imagery CD twice a day for 8 weeks)
Number of subjects: 30
Study 18199015 — intervention group
Group type: COMPARATOR
Intervention: Control group (resting for 25 minutes twice daily for 8 weeks)
Number of subjects: 30
Study 15836942 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic group (n=16)
Number of subjects: 16
Study 15836942 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=10)
Number of subjects: 16
Study 14565594 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg/day) plus calcium (1000 mg/day)
Number of subjects: 77
Study 14565594 — intervention group
Group type: COMPARATOR
Intervention: Calcium alone
Number of subjects: 77
Study 10440419 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 50 mg
Number of subjects: 65
Study 10440419 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg
Number of subjects: 65
Study 10440419 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 100 mg
Number of subjects: 65
Study 10440419 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 150 mg
Number of subjects: 65
Study 10440419 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg (multiple doses for 14 days)
Number of subjects: 65
Study 10440419 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg (long-term study for 12 weeks)
Number of subjects: 65
Study 8985840 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental diet
Number of subjects: 16
Study 8985840 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 16
Study 8985840 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroids
Number of subjects: 16
Study 8985840 — intervention group
Group type: EXPERIMENTAL
Intervention: Rutter A Questionnaire
Number of subjects: 16
Study 8985840 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental concerns
Number of subjects: 16
Study 8985840 — intervention group
Group type: EXPERIMENTAL
Intervention: Absenteeism
Number of subjects: 16
Study 8985840 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction during school work
Number of subjects: 16
Study 8985840 — intervention group
Group type: EXPERIMENTAL
Intervention: Social problems
Number of subjects: 16
Study 8985840 — intervention group
Group type: EXPERIMENTAL
Intervention: Bullying
Number of subjects: 16
Study 8985840 — intervention group
Group type: EXPERIMENTAL
Intervention: Holiday difficulties
Number of subjects: 16
Study 8985840 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour problems
Number of subjects: 16
Study 8985840 — intervention group
Group type: EXPERIMENTAL
Intervention: Disruption of work
Number of subjects: 16
Study 8985840 — intervention group
Group type: EXPERIMENTAL
Intervention: Taking holidays
Number of subjects: 16
Study 1815302 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine (120 mg orally)
Number of subjects: 10
Study 1815302 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine plus GHRH (1 micrograms/kg b.w. i.v.)
Number of subjects: 10
Study 1815302 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine plus GHRH
Number of subjects: 10
Study 6368445 — intervention group
Group type: EXPERIMENTAL
Intervention: De-Nol
Number of subjects: 40
Study 6368445 — intervention group
Group type: COMPARATOR
Intervention: Antacid mixture
Number of subjects: 40
Study 30221619 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief cognitive-behavioural therapy
Number of subjects: 0
Study 30221619 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 29582631 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention based on Protection Motivation Theory (PMT) over six sessions
Number of subjects: 143
Study 29582631 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 143
Study 29582631 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 143
Study 27010625 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab administered monthly
Number of subjects: 1097
Study 27010625 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab administered as needed (PRN)
Number of subjects: 1097
Study 27010625 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg ranibizumab administered monthly
Number of subjects: 1097
Study 27010625 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg ranibizumab administered as needed (PRN)
Number of subjects: 1097
Study 27010625 — intervention group
Group type: EXPERIMENTAL
Intervention: PRN treatment
Number of subjects: 1097
Study 27010625 — intervention group
Group type: EXPERIMENTAL
Intervention: Early responders
Number of subjects: 1097
Study 27010625 — intervention group
Group type: EXPERIMENTAL
Intervention: Early responders vs delayed responders at baseline
Number of subjects: 1097
Study 25439809 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment (67 μg/kg/day) for 1 year followed by 2 years of randomized GH treatment (67 μg/kg/day, 35 μg/kg/day, or IGF‐I titrated)
Number of subjects: 18
Study 25439809 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 18
Study 22824537 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based educational intervention (two sessions at the patient's home, one with the patient and one with their social network)
Number of subjects: 160
Study 22824537 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 160
Study 21211259 — intervention group
Group type: EXPERIMENTAL
Intervention: Single B-Twin expandable spinal spacer
Number of subjects: 45
Study 21211259 — intervention group
Group type: EXPERIMENTAL
Intervention: Double B-Twin expandable spinal spacer
Number of subjects: 45
Study 21211259 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Single and Double B-Twin expandable spinal spacer
Number of subjects: 45
Study 18284652 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose (10 g b.d.)
Number of subjects: 10
Study 18284652 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene glycol (PEG 4000)
Number of subjects: 10
Study 16321128 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training program
Number of subjects: 133
Study 16321128 — intervention group
Group type: COMPARATOR
Intervention: Control group (standardised educational session about exercise rehabilitation)
Number of subjects: 133
Study 14527648 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-cm HHC-based VAS
Number of subjects: 96
Study 14527648 — intervention group
Group type: COMPARATOR
Intervention: 10-cm paper-based VAS
Number of subjects: 96
Study 14527648 — intervention group
Group type: EXPERIMENTAL
Intervention: HHC-based items
Number of subjects: 96
Study 14527648 — intervention group
Group type: EXPERIMENTAL
Intervention: HHC-based VAS
Number of subjects: 96
Study 11230031 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal psychoanalytic psychotherapy for 1 year
Number of subjects: 84
Study 11230031 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-analytic therapy (CAT) for 7 months
Number of subjects: 84
Study 11230031 — intervention group
Group type: EXPERIMENTAL
Intervention: Family therapy for 1 year
Number of subjects: 84
Study 11230031 — intervention group
Group type: COMPARATOR
Intervention: Low contact, 'routine' treatment for 1 year
Number of subjects: 84
Study 9407746 — intervention group
Group type: EXPERIMENTAL
Intervention: Running at a grade of -1.8%
Number of subjects: 13
Study 9407746 — intervention group
Group type: EXPERIMENTAL
Intervention: Running at a grade of -3.6%
Number of subjects: 13
Study 9407746 — intervention group
Group type: EXPERIMENTAL
Intervention: Running at a grade of -5.4%
Number of subjects: 13
Study 9407746 — intervention group
Group type: COMPARATOR
Intervention: Level running (0% grade)
Number of subjects: 13
Study 7684457 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% NaCl (HS)
Number of subjects: 0
Study 7684457 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% NaCl in 6% dextran 70 (HSD)
Number of subjects: 0
Study 7684457 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 0
Study 3427224 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide plus Adriamycin followed by high-dose methotrexate plus cisplatin
Number of subjects: 20
Study 3427224 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate plus cisplatin followed by Cyclophosphamide plus Adriamycin
Number of subjects: 20
Study 31670794 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300mg
Number of subjects: 86
Study 31670794 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150mg
Number of subjects: 86
Study 31670794 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150mg no load
Number of subjects: 86
Study 31670794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 31863697 — intervention group
Group type: EXPERIMENTAL
Intervention: Three option multiple-choice questions (MCQs)
Number of subjects: 3
Study 31863697 — intervention group
Group type: COMPARATOR
Intervention: Four option multiple-choice questions (MCQs)
Number of subjects: 3
Study 29160391 — intervention group
Group type: EXPERIMENTAL
Intervention: Nano Silver Fluoride (NSF)
Number of subjects: 12
Study 29160391 — intervention group
Group type: COMPARATOR
Intervention: Negative control (saline solution)
Number of subjects: 12
Study 25466604 — intervention group
Group type: EXPERIMENTAL
Intervention: Small media print intervention (SMPI)
Number of subjects: 665
Study 25466604 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored interactive multimedia intervention (TIMI)
Number of subjects: 665
Study 25466604 — intervention group
Group type: COMPARATOR
Intervention: No intervention (comparison group)
Number of subjects: 665
Study 23358760 — intervention group
Group type: EXPERIMENTAL
Intervention: P2 Group (more intensive educational nutritional intervention)
Number of subjects: 52
Study 23358760 — intervention group
Group type: COMPARATOR
Intervention: P1 Group (less intensive educational nutritional intervention)
Number of subjects: 52
Study 23358760 — intervention group
Group type: EXPERIMENTAL
Intervention: P2 Group
Number of subjects: 52
Study 21597989 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg methylphenidate
Number of subjects: 0
Study 21597989 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg methylphenidate
Number of subjects: 0
Study 21597989 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg methylphenidate
Number of subjects: 0
Study 21597989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21597989 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (all doses)
Number of subjects: 0